Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 75

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 75
---
 *) |
| Loss for the period                 |     |                    |   987 |   |     |     |  436 |

| *) |     | less than 1 thousand |

Research and Development Expenses

Predecessor’s research and development
expenses totaled $846 thousand for the year ended December 31, 2023, representing an increase of $522 thousand, or 161.1%, compared to
$324 thousand for the year ended December 31, 2022. The increase was primarily attributable to the increase in salaries to our employees,
increase in share-based payment expenses and increase in fees paid to our consultants and service providers following expansion of our
research and development agreement with Yissum.

<div align='center'>44</div>

General and Administrative Expenses

Predecessor’s general and administrative
expenses totaled $156 thousand for the year ended December 31, 2023, representing an increase of $44 thousand, or 39.3%, compared to
$112 thousand for the year ended December 31, 2022. The increase was primarily attributable to an increase in professional services expenses.

Operating Loss

As a result of the foregoing, Predecessor’s
operating loss totaled $1,002 thousand for the year ended December 31, 2023, representing an increase of $566 thousand, or 129.8%, compared
to $436 thousand for the year ended December 31, 2022.

Financing income, Net

Predecessor’s recognized financing income,
net of $15 thousand for the year ended December 31, 2023, representing an increase of $15 thousand, or 100.0%, compared to approximately
nil for the year ended December 31, 2022. The increase was primarily attributable to exchange rate differences between the U.S. dollar
and the New Israeli Shekel.

Net and Comprehensive Loss

As a result of the foregoing, Predecessor’s
loss totaled $987 thousand for the year ended December 31, 2023, representing an increase of $551 thousand, or 126.4%, compared to $436
thousand for the year ended December 31, 2022.

Liquidity

To date, the Company has not generated any
revenues from its current operations, incurred losses, and therefore is dependent upon external sources for financing its operations.
As of June 30, 2025, the Company had an accumulated deficit of $13,119 thousands. To support its operations